1. Home
  2. LCFY vs BRTX Comparison

LCFY vs BRTX Comparison

Compare LCFY & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

HOLD

Current Price

$2.58

Market Cap

8.3M

Sector

N/A

ML Signal

HOLD

Logo BioRestorative Therapies Inc. (NV)

BRTX

BioRestorative Therapies Inc. (NV)

HOLD

Current Price

$0.21

Market Cap

7.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCFY
BRTX
Founded
2009
1997
Country
Australia
United States
Employees
N/A
N/A
Industry
Managed Health Care
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
7.1M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
LCFY
BRTX
Price
$2.58
$0.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
11.5K
333.4K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$81,000.00
Revenue This Year
N/A
$298.39
Revenue Next Year
N/A
$64.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.10
$0.16
52 Week High
$7.75
$1.89

Technical Indicators

Market Signals
Indicator
LCFY
BRTX
Relative Strength Index (RSI) 44.88 39.60
Support Level $2.50 $0.19
Resistance Level $2.81 $0.30
Average True Range (ATR) 0.14 0.02
MACD 0.06 0.00
Stochastic Oscillator 67.47 74.25

Price Performance

Historical Comparison
LCFY
BRTX

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About BRTX BioRestorative Therapies Inc. (NV)

BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.

Share on Social Networks: